TrialMulticenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Trial details
- Registry ID
- NCT07494305
- Phase
- Phase 2
Drug research
LB-102
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305 | LBRX | Phase 2 | Recruiting | 2028-02Estimated |
| 52-week Open Label Safety-Tolerability StudyNCT07369154 | LBRX | Phase 3 | Recruiting | 2028-12Estimated |
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 | LBRX | Phase 2 | Completed | 2024-12-04Actual |
52-week Open Label Safety-Tolerability Study
Trial details
- Registry ID
- NCT07369154
- Phase
- Phase 3
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Trial details
- Registry ID
- NCT06179108
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |